Novel Lead Optimization Strategy Using Quantitative Structure-Activity Relationship and Physiologically-Based Pharmacokinetics Modeling |
Byeon, Jin-Ju
(College of Pharmacy, Chungnam National University)
Park, Min-Ho (College of Pharmacy, Chungnam National University) Shin, Seok-Ho (College of Pharmacy, Chungnam National University) Shin, Young Geun (College of Pharmacy, Chungnam National University) |
1 | Wenlock, M. C., Austin, R. P., Barton, P., Davis, A. M. and Leeson, P. D. : A comparison of physiochemical property profiles of development and marketed oral drugs. J. Med. Chem. 46, 1250 (2003). DOI |
2 | Gleeson, M. P., Hersey, A., Montanari, D. and Overington, J. : Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat. Rev. Drug Discov. 10, 197 (2011). DOI |
3 | Kenny, J. R. : Predictive DMPK: in silico ADME predictions in drug discovery. Mol. Pharm. 10, 1151 (2013). DOI |
4 | U.S. Food and drug administration, http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292923.pdf. |
5 | Jones, H. and Rowland-Yeo, K. : Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst. Pharmacol. 2, e63 (2013). DOI |
6 | Grime, K. H., Barton, P. and McGinnity, D. F. : Application of in silico, in vitro and preclinical pharmacokinetic data for the effective and efficient prediction of human pharmacokinetics. Mol. Pharm. 10, 1191 (2013). DOI |
7 | Ortwine, D. F. and Aliagas, I. : Physicochemical and DMPK in silico models: facilitating their use by medicinal chemists. Mol. Pharm. 10, 1153 (2013). DOI |
8 | Hosea, N. A. and Jones, H. M. : Predicting pharmacokinetic profiles using in silico derived parameters. Mol. Pharm. 10, 1207 (2013). DOI |
9 | Rueeger, H., Lueoend, R., Rogel, O., Rondeau, J. M., Mobitz, H., Machauer, R., Jacobson, L., Staufenbiel, M., Desrayaud, S. and Neumann, U. : Discovery of cyclic sulfone hydroxyethylamines as potent and selective beta-site APPcleaving enzyme 1 (BACE1) inhibitors : structure-based design and in vivo reduction of amyloid beta-peptides. J. Med. Chem. 55, 3364 (2012). DOI |
10 | 의약화학 편집위원회 : 의약화학, 개정판, 신일북스, 서울 p. 47 (2011). |
11 | Wager, T. T., Hou, X., Verhoest, P. R. and Villalobos, A. : Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem. Neurosci. 1, 435 (2010). DOI |
12 | Rowland, M., Peck, C. and Tucker, G. : Physiologically-based pharmacokinetics in drug development and regulatory science. Annu. Rev. Pharmacol. Toxicol. 51, 45 (2011). DOI |
13 | Khalil, F. and Laer, S. : Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug. AAPS J. 16, 226 (2014). DOI |
14 | Maharaj, A., Barrett, J. and Edginton, A. : A workflow example of PBPK modeling to support pediatric research and development : case study with lorazepam. AAPS J. 15, 455 (2013). DOI |
15 | Yusof, I., Shah, F., Hashimoto, T., Segall, M. D. and Greene, N. : Finding the rules for successful drug optimisation. Drug Discov. Today 19, 680 (2014). DOI |
16 | U.S. Food and drug administration, http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205552s002lbl.pdf. |